| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_6cfc033f059d282fcd915bc8be2ae53f |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-00 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-395
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07K16-1214 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K38-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12P21-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-24
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K16-12 |
| filingDate |
1990-03-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_d1c91ffdde5f69431294c39fa330ec7c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_81d1a4638a30958dcd8b487e6e604842
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2586045169f048208b4b3fd1310321da
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_27065ca118b8227578bbd5bd68bec7c2
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_a962be8f7735cfae7bd092c297fa5455
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_7ca9c55c29e63c948e5bf6b24134c680
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_32d60e61126fd664a2de12c72623334e
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_6ab903c315f02adf9d44a7d7d8d34063
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_77eb5139c134816b5e9e968d12ae3d3b |
| publicationDate |
1990-10-04-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
WO-9011350-A1 |
| titleOfInvention |
Human monoclonal antibody reactive with pseudomonas aeruginosa, cell which produces the antibody, method of production, and pharmaceutical preparation |
| abstract |
A new human-human hybridoma which can secrete large amounts of human monoclonal antibodies which are reactive with at least one serotype of principal causative bacteria of Pseudomonas aeruginosa infections in a serum-free medium. Pharmaceutical preparations comprising various combinations of the obtained antibodies are excellent in the effect of preventing or treating Pseudomonas aeruginosa infections. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102517256-B
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-102517256-A |
| priorityDate |
1989-03-20-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |